Keri N Althoff1, Kelly A Gebo2, Richard D Moore2, Cynthia M Boyd2, Amy C Justice3, Cherise Wong4, Gregory M Lucas2, Marina B Klein5, Mari M Kitahata6, Heidi Crane6, Michael J Silverberg7, M John Gill8, William Christopher Mathews9, Robert Dubrow10, Michael A Horberg11, Charles S Rabkin12, Daniel B Klein7, Vincent Lo Re13, Timothy R Sterling14, Fidel A Desir4, Kenneth Lichtenstein15, James Willig16, Anita R Rachlis17, Gregory D Kirk4, Kathryn Anastos18, Frank J Palella19, Jennifer E Thorne2, Joseph Eron20, Lisa P Jacobson4, Sonia Napravnik20, Chad Achenbach19, Angel M Mayor21, Pragna Patel22, Kate Buchacz22, Yuezhou Jing4, Stephen J Gange4. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. Electronic address: kalthoff@jhu.edu. 2. Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD, USA. 3. Yale School of Medicine, New Haven, CT, USA; Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA. 4. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA. 5. McGill University, Montreal, QC, Canada, USA. 6. University of Washington, Seattle, WA, USA. 7. Kaiser Permanente Northern California, Oakland, CA, USA. 8. University of Calgary, Calgary, AB, Canada. 9. University of California San Diego, San Diego, CA, USA. 10. Yale School of Public Health, New Haven, CT, USA. 11. Kaiser Permanente Mid-Atlantic Permanente Medical Group, Rockville, MD, USA. 12. National Cancer Institute, Bethesda, MD, USA. 13. University of Pennsylvania, Philadelphia, PA, USA. 14. Vanderbilt University Medical Center, Nashville, TN, USA. 15. National Jewish Health, Denver, CO, USA. 16. University of Alabama, Birmingham, AL, USA. 17. Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. 18. Albert Einstein College of Medicine, New York, NY, USA. 19. Northwestern University, Chicago, IL, USA. 20. University of North Carolina, Chapel Hill, NC, USA. 21. Universidad Central del Caribe, Puerto Rico, USA. 22. Centers for Disease Control and Prevention, Atlanta, GA, USA.
Abstract
BACKGROUND: Adults with HIV have an increased burden of non-AIDS-defining cancers, myocardial infarction, end-stage liver disease, and end-stage renal disease. The objective of this study was to estimate the population attributable fractions (PAFs) of preventable or modifiable HIV-related and traditional risk factors for non-AIDS-defining cancers, myocardial infarction, end-stage liver disease, and end-stage renal disease outcomes. METHODS: We included participants receiving care in academic and community-based outpatient HIV clinical cohorts in the USA and Canada from Jan 1, 2000, to Dec 31, 2014, who contributed to the North American AIDS Cohort Collaboration on Research and Design and who had validated non-AIDS-defining cancers, myocardial infarction, end-stage liver disease, or end-stage renal disease outcomes. Traditional risk factors were tobacco smoking, hypertension, elevated total cholesterol, type 2 diabetes, renal impairment (stage 4 chronic kidney disease), and hepatitis C virus and hepatitis B virus infections. HIV-related risk factors were low CD4 count (<200 cells per μL), detectable plasma HIV RNA (>400 copies per mL), and history of a clinical AIDS diagnosis. PAFs and 95% CIs were estimated to quantify the proportion of outcomes that could be avoided if the risk factor was prevented. FINDINGS: In each of the study populations for the four outcomes (1405 of 61 500 had non-AIDS-defining cancer, 347 of 29 515 had myocardial infarctions, 387 of 35 044 had end-stage liver disease events, and 255 of 35 620 had end-stage renal disease events), about 17% were older than 50 years at study entry, about 50% were non-white, and about 80% were men. Preventing smoking would avoid 24% (95% CI 13-35) of these cancers and 37% (7-66) of the myocardial infarctions. Preventing elevated total cholesterol and hypertension would avoid the greatest proportion of myocardial infarctions: 44% (30-58) for cholesterol and 42% (28-56) for hypertension. For liver disease, the PAF was greatest for hepatitis C infection (33%; 95% CI 17-48). For renal disease, the PAF was greatest for hypertension (39%; 26-51) followed by elevated total cholesterol (22%; 13-31), detectable HIV RNA (19; 9-31), and low CD4 cell count (13%; 4-21). INTERPRETATION: The substantial proportion of non-AIDS-defining cancers, myocardial infarction, end-stage liver disease, and end-stage renal disease outcomes that could be prevented with interventions on traditional risk factors elevates the importance of screening for these risk factors, improving the effectiveness of prevention (or modification) of these risk factors, and creating sustainable care models to implement such interventions during the decades of life of adults living with HIV who are receiving care. FUNDING: National Institutes of Health, US Centers for Disease Control and Prevention, the US Agency for Healthcare Research and Quality, the US Health Resources and Services Administration, the Canadian Institutes of Health Research, the Ontario Ministry of Health and Long Term Care, and the Government of Alberta.
BACKGROUND: Adults with HIV have an increased burden of non-AIDS-defining cancers, myocardial infarction, end-stage liver disease, and end-stage renal disease. The objective of this study was to estimate the population attributable fractions (PAFs) of preventable or modifiable HIV-related and traditional risk factors for non-AIDS-defining cancers, myocardial infarction, end-stage liver disease, and end-stage renal disease outcomes. METHODS: We included participants receiving care in academic and community-based outpatient HIV clinical cohorts in the USA and Canada from Jan 1, 2000, to Dec 31, 2014, who contributed to the North American AIDS Cohort Collaboration on Research and Design and who had validated non-AIDS-defining cancers, myocardial infarction, end-stage liver disease, or end-stage renal disease outcomes. Traditional risk factors were tobacco smoking, hypertension, elevated total cholesterol, type 2 diabetes, renal impairment (stage 4 chronic kidney disease), and hepatitis C virus and hepatitis B virus infections. HIV-related risk factors were low CD4 count (<200 cells per μL), detectable plasma HIV RNA (>400 copies per mL), and history of a clinical AIDS diagnosis. PAFs and 95% CIs were estimated to quantify the proportion of outcomes that could be avoided if the risk factor was prevented. FINDINGS: In each of the study populations for the four outcomes (1405 of 61 500 had non-AIDS-defining cancer, 347 of 29 515 had myocardial infarctions, 387 of 35 044 had end-stage liver disease events, and 255 of 35 620 had end-stage renal disease events), about 17% were older than 50 years at study entry, about 50% were non-white, and about 80% were men. Preventing smoking would avoid 24% (95% CI 13-35) of these cancers and 37% (7-66) of the myocardial infarctions. Preventing elevated total cholesterol and hypertension would avoid the greatest proportion of myocardial infarctions: 44% (30-58) for cholesterol and 42% (28-56) for hypertension. For liver disease, the PAF was greatest for hepatitis C infection (33%; 95% CI 17-48). For renal disease, the PAF was greatest for hypertension (39%; 26-51) followed by elevated total cholesterol (22%; 13-31), detectable HIV RNA (19; 9-31), and low CD4 cell count (13%; 4-21). INTERPRETATION: The substantial proportion of non-AIDS-defining cancers, myocardial infarction, end-stage liver disease, and end-stage renal disease outcomes that could be prevented with interventions on traditional risk factors elevates the importance of screening for these risk factors, improving the effectiveness of prevention (or modification) of these risk factors, and creating sustainable care models to implement such interventions during the decades of life of adults living with HIV who are receiving care. FUNDING: National Institutes of Health, US Centers for Disease Control and Prevention, the US Agency for Healthcare Research and Quality, the US Health Resources and Services Administration, the Canadian Institutes of Health Research, the Ontario Ministry of Health and Long Term Care, and the Government of Alberta.
Authors: Stephen J Gange; Mari M Kitahata; Michael S Saag; David R Bangsberg; Ronald J Bosch; John T Brooks; Liviana Calzavara; Steven G Deeks; Joseph J Eron; Kelly A Gebo; M John Gill; David W Haas; Robert S Hogg; Michael A Horberg; Lisa P Jacobson; Amy C Justice; Gregory D Kirk; Marina B Klein; Jeffrey N Martin; Rosemary G McKaig; Benigno Rodriguez; Sean B Rourke; Timothy R Sterling; Aimee M Freeman; Richard D Moore Journal: Int J Epidemiol Date: 2007-01-08 Impact factor: 7.196
Authors: R Weber; M Ruppik; M Rickenbach; A Spoerri; H Furrer; M Battegay; M Cavassini; A Calmy; E Bernasconi; P Schmid; M Flepp; J Kowalska; B Ledergerber Journal: HIV Med Date: 2012-09-24 Impact factor: 3.180
Authors: Nina Friis-Møller; Rainer Weber; Peter Reiss; Rodolphe Thiébaut; Ole Kirk; Antonella d'Arminio Monforte; Christian Pradier; Linda Morfeldt; Silvia Mateu; Matthew Law; Wafaa El-Sadr; Stephan De Wit; Caroline A Sabin; Andrew N Phillips; Jens D Lundgren Journal: AIDS Date: 2003-05-23 Impact factor: 4.177
Authors: Stephanie Shiau; Alexis A Bender; Jane A O'Halloran; Erin Sundermann; Juhi Aggarwal; Keri N Althoff; Jason V Baker; Steven Deeks; Linda P Fried; Stephen Karpiak; Maile Y Karris; Thomas D Marcotte; Jean B Nachega; Joseph B Margolick; Kristine M Erlandson; David J Moore Journal: AIDS Res Hum Retroviruses Date: 2020-09-23 Impact factor: 2.205
Authors: Keri N Althoff; Cameron N Stewart; Elizabeth Humes; Jinbing Zhang; Lucas Gerace; Cynthia M Boyd; Cherise Wong; Amy C Justice; Kelly A Gebo; Jennifer E Thorne; Anna A Rubtsova; Michael A Horberg; Michael J Silverberg; Sean X Leng; Peter F Rebeiro; Richard D Moore; Kate Buchacz; Parastu Kasaie Journal: AIDS Date: 2022-03-01 Impact factor: 4.177
Authors: Joyonna Carrie Gamble-George; Christopher T Longenecker; Allison R Webel; David H Au; Arleen F Brown; Hayden Bosworth; Kristina Crothers; William E Cunningham; Kevin A Fiscella; Alison B Hamilton; Christian D Helfrich; Joseph A Ladapo; Amneris Luque; Jonathan N Tobin; Gail E Wyatt Journal: Prog Cardiovasc Dis Date: 2020-03-19 Impact factor: 8.194
Authors: Derek D Satre; Tory Levine-Hall; Stacy A Sterling; Kelly C Young-Wolff; Jennifer O Lam; Stacey Alexeeff; J Carlo Hojilla; Andrew Williams; Amy C Justice; Jonathan Sterne; Matthias Cavassini; Kendall J Bryant; Emily C Williams; Michael A Horberg; Paul Volberding; Constance Weisner; Michael J Silverberg Journal: Drug Alcohol Depend Date: 2021-01-08 Impact factor: 4.492
Authors: Jessie K Edwards; Stephen R Cole; Tiffany L Breger; Jacqueline E Rudolph; Lindsey M Filiatreau; Kate Buchacz; Elizabeth Humes; Peter F Rebeiro; Gypsyamber D'Souza; M John Gill; Michael J Silverberg; W Christopher Mathews; Michael A Horberg; Jennifer Thorne; H Irene Hall; Amy Justice; Vincent C Marconi; Viviane D Lima; Ronald J Bosch; Timothy R Sterling; Keri N Althoff; Richard D Moore; Michael Saag; Joseph J Eron Journal: Ann Intern Med Date: 2021-07-06 Impact factor: 25.391
Authors: Meena S Madhur; Fernando Elijovich; Matthew R Alexander; Ashley Pitzer; Jeanne Ishimwe; Justin P Van Beusecum; David M Patrick; Charles D Smart; Thomas R Kleyman; Justin Kingery; Robert N Peck; Cheryl L Laffer; Annet Kirabo Journal: Circ Res Date: 2021-04-01 Impact factor: 17.367
Authors: Lauren F Collins; Anandi N Sheth; C Christina Mehta; Susanna Naggie; Elizabeth T Golub; Kathryn Anastos; Audrey L French; Seble Kassaye; Tonya N Taylor; Margaret A Fischl; Adaora A Adimora; Mirjam-Colette Kempf; Frank J Palella; Phyllis C Tien; Ighovwerha Ofotokun Journal: Clin Infect Dis Date: 2021-10-05 Impact factor: 9.079